A new treatment for schizophrenia – backed by Wellcome-funded research – has the potential to change the lives of millions of people living with the condition globally.
Schizophrenia is a severe, long-term mental health condition that affects around 1 in 300 people worldwide.
While there are different treatment options available, antipsychotic drugs are commonly used to treat the condition, but they don’t work for everyone.
Now, a new combination drug called Cobenfy has been approved by the US Food and Drug Administration (FDA). It is the first new pharmacological approach for treating schizophrenia in over 50 years and may provide an alternative option for people living with the condition.
🔔 Subscribe to Wellcome on YouTube: https://wellc.me/3Blh0c1